Skip to main content

previous disabled Page of 2
and
  1. Article

    Open Access

    Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study

    Reliable detection of JAK2-V617F is critical for accurate diagnosis of myeloproliferative neoplasms (MPNs); in addition, sensitive mutation-specific assays can be applied to monitor disease response. However, the...

    J V Jovanovic, A Ivey, A M Vannucchi, E Lippert, E Oppliger Leibundgut in Leukemia (2013)

  2. No Access

    Article

    Mutations and prognosis in primary myelofibrosis

    Patient outcome in primary myelofibrosis (PMF) is significantly influenced by karyotype. We studied 879 PMF patients to determine the individual and combinatorial prognostic relevance of somatic mutations. Ana...

    A M Vannucchi, T L Lasho, P Guglielmelli, F Biamonte, A Pardanani, A Pereira in Leukemia (2013)

  3. Article

    Open Access

    Preoperative ultrasound and FNA in the diagnosis of axillary involvement in invasive breast cancer: correlation with intraoperative one-stop nucleic acid amplification and final histology

    EK Jackson, N Howes, A Jones, Z Rayter, A Valencia in Breast Cancer Research (2012)

  4. Article

    Open Access

    Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients

    The role of CHAC1 (cation transport regulator-like protein 1), a recently identified component of the unfolded protein response (UPR) pathway, in gynaecological cancers has not yet been characterised. Now, thi...

    G Goebel, R Berger, A M Strasak, D Egle, E Müller-Holzner in British Journal of Cancer (2012)

  5. Article

    Open Access

    The treatment of early breast cancer in women over the age of 70

    One third of all breast cancers are diagnosed in women aged 70 or over. Older women are a heterogeneous population who are under-represented in clinical trials, and as a result uncertainty can exist as to what...

    A Ring, M Reed, R Leonard, I Kunkler, H Muss, H Wildiers in British Journal of Cancer (2011)

  6. Article

    Genetic analysis of lobular carcinoma in situ and associated invasive lobular cancer

    LR Yates, A Jones, H Patel, A Mackay, C Gillett, S Pinder in Breast Cancer Research (2010)

  7. Article

    Open Access

    Idiopathic venous thromboembolic disease is associated with a poorer prognosis from subsequent malignancy

    We carried out a retrospective study of prognosis in Scottish patients diagnosed with cancer within 5 years after a venous thromboembolism (VTE).

    A Jones, D L Stockton, A J Simpson, J T Murchison in British Journal of Cancer (2009)

  8. No Access

    Article

    Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1

    Imatinib is usually a highly effective treatment for myeloproliferative neoplasms (MPNs) associated with ABL, PDGFRA or PDGFRB gene fusions; however, occasional imatinib-responsive patients have been reported wit...

    A Chase, B Schultheis, S Kreil, J Baxter, C Hidalgo-Curtis, A Jones, L Zhang in Leukemia (2009)

  9. Article

    Open Access

    Waiting times for systemic cancer therapy in the United Kingdom in 2006

    This audit was conducted to measure waiting times for systemic cancer therapy across the United Kingdom. All patients, aged 16 years or older, commencing their first course of systemic therapy between 13 Novem...

    M V Williams, K J Drinkwater, A Jones, B O'Sullivan, D Tait in British Journal of Cancer (2008)

  10. No Access

    Article

    JAK2 Mutations are present in all cases of polycythemia vera

    Y L Wang, K Vandris, A Jones, N C P Cross, P Christos, F Adriano, R T Silver in Leukemia (2008)

  11. No Access

    Article

    Patient satisfaction with nurse-led telephone consultation for the follow-up of patients with prostate cancer

    Prostate cancer is being diagnosed earlier and in higher numbers than ever before. The nature of the disease means many patients have to be monitored regularly and for a prolonged period leading to increased p...

    N Shaida, C Jones, N Ravindranath, T Das in Prostate Cancer and Prostatic Diseases (2007)

  12. Article

    Open Access

    Medical student teaching in the UK: how well are newly qualified doctors prepared for their role caring for patients with cancer in hospital?

    A number of studies have identified problems with undergraduate oncology teaching. We have investigated how well prepared newly qualified doctors (first foundation year, or FY1 doctors) are for treating patien...

    J Cave, K Woolf, J Dacre, H W W Potts, A Jones in British Journal of Cancer (2007)

  13. No Access

    Article

    Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours

    Patient’s preference is for oral chemotherapy when both oral and i.v. are available, provided that efficacy is equivalent. Reliable switch from oral to i.v. is possible if correspondence between respective dos...

    H. Bourgeois, J. Vermorken, G. Dark, A. Jones in Cancer Chemotherapy and Pharmacology (2007)

  14. No Access

    Article

    Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma

    A simple high throughput micro-fluorescence in situ hybridisation technique (FISH) was used to detect chromosome 13 deletions (Δ13), immunoglobulin heavy chain (IgH) rearrangements, t(11;14)(q13;q32), t(4;14)(p16...

    F M Ross, A H Ibrahim, A Vilain-Holmes, M O Winfield, L Chiecchio in Leukemia (2005)

  15. Article

    Open Access

    Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study

    The combination of intravenous (i.v.) vinorelbine and epirubicin is highly active in the treatment of metastatic breast cancer (MBC). In an effort to improve patient convenience, we investigated a regimen alte...

    D Serin, M Verrill, A Jones, T Delozier, R Coleman in British Journal of Cancer (2005)

  16. Article

    Open Access

    Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma

    Suramin is an antitrypanosomal agent with antineoplastic activity, but with serious systemic side effects. We administered Suramin intravesically to determine a concentration with low toxicity but with evidenc...

    J J Ord, E Streeter, A Jones, K Le Monnier, D Cranston, J Crew in British Journal of Cancer (2005)

  17. Article

    Open Access

    Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma

    Elevated thymidine phosphorylase has been shown to correlate with increased angiogenesis and poor prognosis in many cancers including transitional cell carcinoma of the bladder. In vitro studies have demonstrated...

    N S Brown, E H Streeter, A Jones, A L Harris, R Bicknell in British Journal of Cancer (2005)

  18. Article

    Assessment clinics at 'Avon Breast Screening Unit': what has changed in 5 years?

    S Chakrabarthi, A Jones, E Kutt in Breast Cancer Research (2004)

  19. No Access

    Article

    A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen

    Idoxifene is a novel selective oestrogen receptor modulator (SERM) which had greater binding affinity for the oestrogen receptor (ER) and reduced agonist activity compared with tamoxifen in preclinical studies...

    S. R. D. Johnston, L. A. Gumbrell, T. R. J. Evans in Cancer Chemotherapy and Pharmacology (2004)

  20. Article

    Open Access

    Trends in postoperative radiotherapy delay and the effect on survival in breast cancer patients treated with conservation surgery

    The adequate timing of adjuvant radiotherapy (RT) in breast cancer has become a subject of increasing interest in recent years. A population-based study was undertaken to determine the influence of demographic...

    J Stefoski Mikeljevic, R Haward, C Johnston, A Crellin in British Journal of Cancer (2004)

previous disabled Page of 2